Equity Overview
Price & Market Data
Price: $3.02
Daily Change: +$0.73 / 24.17%
Range: $2.29 - $3.56
Market Cap: $1,690,835
Volume: 15,147,905
Performance Metrics
1 Week: -52.59%
1 Month: -61.90%
3 Months: -86.33%
6 Months: -98.16%
1 Year: -99.30%
YTD: -97.95%
Company Details
Employees: 18
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.